The global market is expected to enjoy a valuation of US$ 153.6 Million by the end of the year 2023, and further expand at a CAGR of 10.3% to reach a valuation of US$ 408.3 Million by the year 2033. According to the recent study by Future Market Insights, pure gold markers are leading the market with an expected share of about 62.50% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 139.24 Million |
| Market Value 2023 | US$ 153.6 Million |
| Market Value 2033 | US$ 408.3 Million |
| CAGR 2023 to 2033 | 10.3% |
| Market Share of Top 5 Countries | 57.8% |
| Key Market Players | Eckert & Ziegler BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA Dosimetry, Best Medical International, Inc., IZI Medical Products, Carbon Medical Technologies, CIVCO, alphaXRT, Nanovi A/S, Stellar Medical |
Radiation oncologists can benefit significantly from fiducial markers in two ways. They start by pinpointing the tumour’s precise location at each stage of the patient's breathing cycle. Second, they enable the radiation oncologist to guarantee that the delivery is precisely in the proper area every day because imaging is provided on the radiation treatment equipment itself. Smaller margins of healthy tissues within the treated areas are made possible by these two benefits, which reduces side effects.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for fiducial markers was approximately 1.5% of the overall ~US$ 6.5 Billion of the global radiotherapy market in 2022.
Fiducial markers, which are incredibly tiny objects approximately the size of rice grains, can target tumours or other cancerous tissues while excluding healthy ones. A fiducial marker is a device used in radiotherapy to locate the surgical site and administer precise radiation doses. Percutaneous implantation of fiducial markers has been attempted, but these operations have been linked to a high rate of pneumothorax and chest drain placement.
Fiducial markers can be placed easily and safely during bronchoscopy. The fiducial marker can help the doctor locate the tumour accurately so that the patient will receive the right amount of radiation without injuring nearby tissue.
There are numerous different types of fiducial markers, including markers made of metal or polymers, among others. The fiducial marker technology may also offer a 3D image of the fiducials together with a report outlining the precise diagnosis and course of therapy.
The main use of fiducial markers in radiotherapy is to identify lung tumours, also known as lung fiducial markers. When air is wedged between the lung and the chest wall after lung fiducial markers are implanted, the result is a pneumothorax, or collapsed lung. A chest tube may need to be inserted in order to remove the air pocket and re-expand the lung.
Patients with prostate cancer receive treatment using prostate fiducial markers. Rectal bleeding, blood in the urine, and discomfort or stinging when peeing can all result from the improper implementation of prostate fiducial markers in the prostate. The second most common malignancy in men worldwide is prostate cancer. As a result, there is a growing demand for prostate fiducial markers.
The use of cutting-edge technology in hospitals, hospital outpatient facilities, and the medical industry has fuelled the rise of fiducial marker producers over the past ten years, despite the fact that modern lifestyles, a lack of healthy behaviour, and other factors have increased cancer risks. Fiducial markers in radiotherapy are likely to become more popular over the next few years, which will raise demand for manufacturers and suppliers.
Increased awareness of early detection and effective treatment for cancer, as well as rising cancer incidence rates, are driving up demand for fiducial markers. As manufacturers work to offer a wider selection of products, demand for fiducial markers for various disease indication is quickly rising. Thus, owing to the aforementioned factors, the global fiducial markers market is expected to grow at a CAGR of 10.27% during the forecast period from 2023 to 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 9.23% |
| Jul - Dec (H2), 2021 (A) | 11.35% |
| Jan - Jun (H1),2022 Projected (P) | 7.40% |
| Jan - Jun (H1),2022 Outlook (O) | 8.15% |
| Jul - Dec (H2), 2022 Outlook (O) | 12.12% |
| Jul - Dec (H2), 2022 Projected (P) | 11.59% |
| Jan - Jun (H1), 2023 Projected (P) | 8.53% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 75↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | (-) 108↓ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 53↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 77↑ |
Fiducial markers are used in image-based radiotherapy to target malignant areas while sparing healthy tissues. Due to an increase in cancer diagnoses, there is a rising demand for fiducial markers on a global scale.
With over 4 million occurrences annually, lung and breast cancers are the most prevalent cancers in adults globally. As a result, governments and healthcare organisations are working harder to develop extremely complicated procedures to ease the pressure.
Evidence suggests that patients with Stage IV non-small cell lung cancer who have only a few extrapulmonary metastases live longer while receiving extensive radiation therapy. On the other hand, open surgery has proven to be effective for treating cervical malignancies in their early stages. As a result, fiducial markers are in high demand.
Rising demand from hospitals for highly advanced fiducial markers, increasing investments from governments and non-profit organisations on research and development, advanced medical equipment, and other products for hospitals, are fuelling the need for fiducial markers.
Principal Consultant
The cost of fiducial markers is typically prohibitive for most people. Commoners might not be able to afford the high operating costs as a result, which would restrict the market growth for fiducial markers.
The use of fiducial markers has a number of drawbacks. These procedures are not suitable for everyone due to their invasiveness. Fiducial markers also degrade image quality during scanning, making tumour identification challenging. The market's expansion is also constrained by a lack of expertise.
| Country | The USA |
|---|---|
| Market Share (2023) | 22.8% |
| Market Share (2033) | 20.7% |
| BPS Analysis | -201 |
| Country | China |
|---|---|
| Market Share (2023) | 12.7% |
| Market Share (2033) | 14.4% |
| BPS Analysis | 172 |
| Country | Japan |
|---|---|
| Market Share (2023) | 8.8% |
| Market Share (2033) | 9.8% |
| BPS Analysis | 93 |
| Country | Germany |
|---|---|
| Market Share (2023) | 6.6% |
| Market Share (2033) | 6.1% |
| BPS Analysis | -55 |
| Country | UK |
|---|---|
| Market Share (2023) | 6.5% |
| Market Share (2033) | 6.1% |
| BPS Analysis | -42 |
The USA is set to obtain a share of around 22.8% in the global market, in 2023.
This is brought on by an increase in cancer treatment facilities, radiation treatment facilities, and advanced manufacturing facilities. The United States will have 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in 2022, according to Cancer Facts & Figures (2022), an educational companion to Cancer Statistics (2022), a scientific article published in the journal of the American Cancer Society.
These developments will probably accelerate the growth of the fiducial marker market in the United States of America over the next ten years. Likewise, growing market growth is being fuelled by significant manufacturers' presence and expanding fiducial marker sales in the USA
Germany is set to hold a market share of nearly 6.6% in the global fiducial markers market in 2023.
In Europe, more than 3.2 million people are given a cancer diagnosis each year. Breast and colorectal cancer are the most prevalent types of the disease because of population ageing and a rise in obesity prevalence. Additionally, it is projected that extending CE approval of different fiducial markers will help regional market expansion. For instance, in March 2020, Nanovi A/BioXmark S's liquid fiducial marker received CE approval. These developments are set to expand the market in Germany over the projected period.
China will hold a share of around 12.7% in the global market, in 2023.
In China, lung cancer is the most common type of cancer. The incidences of stomach, liver, and esophageal cancer have slowly decreased in China, whereas colorectal cancer, prostate cancer in men, and other seven cancer types in women have increased.
Cut case-fatality rates helped to lower cancer mortality in the nation, while increases in the adult population and population ageing were significant predictors of incremental cancer fatalities in various cancer types. Thus, during the anticipated time, these variables cause the fiducial markers market to rise quickly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The pure gold markers segment leads the market and is expected to hold a share of around 62.5% globally, in 2023.
Fiducial markers made of pure gold are most frequently employed in various cancer treatment procedures. Gold fiducial markers dramatically enhance target visibility during brachytherapy and external beam radiation treatments. It also improved patients' feelings.
The manufacturer of distinctive fiducial markers, InnoMedicus, is the source of the Gold Anchor Marker. It is frequently used for Cyberknife procedures on the liver, pancreas, lungs, adrenal gland, and prostate gland, to name a few. More than six out of ten cancer procedures are likely to utilise gold markers.
Photon therapy segment is set to hold a global market share of around 51.9% in 2023. In order to prepare for radiation therapy, small metal items called fiducial markers are placed in or close to a tumour using imaging guidance. The markers enable the treatment team to give the highest radiation dose to the tumour while sparing healthy tissue and aid in more precise tumour localization. This factor is set to propel the segment growth over the forecast period.
Prostrate site is projected to hold a market share of around 72.2% in the global market in 2023.
To increase contrast and subsequently treatment setup and prostate targeting, fiducial markers (FMs) have been designed and surgically inserted within the prostate gland before radiotherapy planning. There are several different strategies for using prostate FMs when they are used in clinical practise.
The surgical process required to implant FMs into the prostate contains risks such as discomfort, haemorrhage, inflammation, and infection, but overall the operation is safe and well tolerated.
Radiotherapy centers is set to hold a market share of around 39.1% in the global market in 2023.
Fiducial markers provide more precise radiation therapy, increasing the likelihood that the radiation will successfully kill cancer cells and decreasing the likelihood that it would harm healthy cells, minimising the procedure's negative effects.
The use of fiducial markers enables more precise and concentrated radiation therapy for the tumour. It can also significantly shorten the time a patient needs endure radiation therapy. Sometimes a radiation treatment that would normally take five weeks can be completed in just five days, thus propelling the segment share within the global market.
Major firms like CIVCO are releasing implantable fiducial marker solutions with a range of features and settings that prevent the markers' post-placement movement.
Instances of key developmental strategies by the industry players in the fiducial markers market are given below:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the fiducial markers space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Modality, Disease Site, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The projected revenue of the market by 2033 is US$ 408.3 million.
The market CAGR for 2033 is projected to be 10.3%.
The market is valued at US$ 153.6 million in 2023.
North America holds a significant market share.
The challenge for the fiducial markers market is the high cost of fiducial markers.
1. Executive Summary | Fiducial Markers Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Product Adoption/Usage Analysis
4.3. Technological Assessment
4.4. Regulatory Landscape
4.5. Reimbursement Scenario
4.6. Promotional Strategies, By Key Players
4.7. PESTEL Analysis
4.8. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Radiotherapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Burden of Cancer
5.2.2. Rising Adoption of Radiotherapy for Cancer Treatment
5.2.3. Advancements in Technology
5.2.4. Adoption of Devices by Oncologists
5.2.5. Rising Demand for Image Guidance Radiation Therapy (IGRT) and Stereotactic Body Radiation therapy (SBRT)
5.2.6. Limitations With Products
5.2.7. Cost of Markers
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Modality
6.1.3. By Disease Site
6.1.4. By End User
6.1.5. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Product, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
8.3.1. Polymer Based Markers
8.3.2. Metal Based Markers
8.3.3. Pure Gold Markers
8.3.4. Liquid Based Markers
8.4. Market Attractiveness Analysis By Product
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Modality, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Modality, 2023 to 2033
9.3.1. Photon Therapy
9.3.2. Proton Therapy
9.3.3. Tomotherapy
9.3.4. Cyberknife
9.4. Market Attractiveness Analysis By Modality
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Site
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Disease Site, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Site, 2023 to 2033
10.3.1. Head & Neck
10.3.2. Breast
10.3.3. Lung
10.3.4. Abdomen
10.3.5. Prostate
10.3.6. Kidney
10.3.7. Cervix or Other Gynecologic Organs
10.4. Market Attractiveness Analysis By Disease Site
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Cancer Research Institutes
11.3.3. Radiotherapy Centers
11.4. Market Attractiveness Analysis By End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Modality
13.3.4. By Disease Site
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Modality
13.4.4. By Disease Site
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Modality
13.8.1.2.3. By Disease Site
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Modality
13.8.2.2.3. By Disease Site
13.8.2.2.4. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Modality
14.3.4. By Disease Site
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Modality
14.4.4. By Disease Site
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Modality
14.8.1.2.3. By Disease Site
14.8.1.2.4. By End User
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Modality
14.8.2.2.3. By Disease Site
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Modality
14.8.3.2.3. By Disease Site
14.8.3.2.4. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Modality
15.3.4. By Disease Site
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Modality
15.4.4. By Disease Site
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Modality
15.8.1.2.3. By Disease Site
15.8.1.2.4. By End User
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. B By Product
15.8.2.2.2. By Modality
15.8.2.2.3. By Disease Site
15.8.2.2.4. By End User
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Modality
15.8.3.2.3. By Disease Site
15.8.3.2.4. By End User
15.8.4. United Kingdom Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Modality
15.8.4.2.3. By Disease Site
15.8.4.2.4. By End User
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Modality
15.8.5.2.3. By Disease Site
15.8.5.2.4. By End User
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Product
15.8.6.2.2. By Modality
15.8.6.2.3. By Disease Site
15.8.6.2.4. By End User
15.8.7. Russia Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Product
15.8.7.2.2. By Modality
15.8.7.2.3. By Disease Site
15.8.7.2.4. By End User
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product
16.3.3. By Modality
16.3.4. By Disease Site
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Modality
16.4.4. By Disease Site
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Modality
16.8.1.2.3. By Disease Site
16.8.1.2.4. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Modality
16.8.2.2.3. By Disease Site
16.8.2.2.4. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Modality
16.8.3.2.3. By Disease Site
16.8.3.2.4. By End User
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By Modality
17.3.4. By Disease Site
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Modality
17.4.4. By Disease Site
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Modality
17.8.1.2.3. By Disease Site
17.8.1.2.4. By End User
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Modality
17.8.2.2.3. By Disease Site
17.8.2.2.4. By End User
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Modality
17.8.3.2.3. By Disease Site
17.8.3.2.4. By End User
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Modality
17.8.4.2.3. By Disease Site
17.8.4.2.4. By End User
18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Modality
18.3.4. By Disease Site
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Modality
18.4.4. By Disease Site
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Modality
18.8.1.2.3. By Disease Site
18.8.1.2.4. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Modality
18.8.2.2.3. By Disease Site
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Modality
19.3.4. By Disease Site
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Modality
19.4.4. By Disease Site
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Modality
19.8.1.2.3. By Disease Site
19.8.1.2.4. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Modality
19.8.2.2.3. By Disease Site
19.8.2.2.4. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Modality
19.8.3.2.3. By Disease Site
19.8.3.2.4. By End User
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Modality
19.8.4.2.3. By Disease Site
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Eckert & Ziegler BEBIG
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Product Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Innovative Oncology Solutions
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financials
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.2.6.1. Marketing Strategy
21.3.2.6.2. Product Strategy
21.3.2.6.3. Channel Strategy
21.3.3. Boston Scientific
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financials
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.3.6.1. Marketing Strategy
21.3.3.6.2. Product Strategy
21.3.3.6.3. Channel Strategy
21.3.4. IBA Dosimetry
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financials
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.4.6.1. Marketing Strategy
21.3.4.6.2. Product Strategy
21.3.4.6.3. Channel Strategy
21.3.5. Best Medical International, Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financials
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.5.6.1. Marketing Strategy
21.3.5.6.2. Product Strategy
21.3.5.6.3. Channel Strategy
21.3.6. IZI Medical Products
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financials
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.6.6.1. Marketing Strategy
21.3.6.6.2. Product Strategy
21.3.6.6.3. Channel Strategy
21.3.7. Carbon Medical Technologies
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financials
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.7.6.1. Marketing Strategy
21.3.7.6.2. Product Strategy
21.3.7.6.3. Channel Strategy
21.3.8. CIVCO
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financials
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.8.6.1. Marketing Strategy
21.3.8.6.2. Product Strategy
21.3.8.6.3. Channel Strategy
21.3.9. alphaXRT
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financials
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.9.6.1. Marketing Strategy
21.3.9.6.2. Product Strategy
21.3.9.6.3. Channel Strategy
21.3.10. Nanovi A/S
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Key Financials
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
21.3.10.6.1. Marketing Strategy
21.3.10.6.2. Product Strategy
21.3.10.6.3. Channel Strategy
21.3.11. Stellar Medical
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Sales Footprint
21.3.11.4. Key Financials
21.3.11.5. SWOT Analysis
21.3.11.6. Strategy Overview
21.3.11.6.1. Marketing Strategy
21.3.11.6.2. Product Strategy
21.3.11.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Fiducial Markers Market
